Navigation Links
Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07,Teleconference to Answer Questions About TA-65, Their Telomerase,Activator With Proven Age Management Benefits

NEW YORK, June 15, 2007 /PRNewswire/ -- Telomerase Activation Sciences, Inc. (T.A. Sciences) recently announced the results of the Pivotal 2005 Anti-Aging Trial of TA-65, the first human trial ever to show demonstrated, measurable and positive anti-aging benefits from a Telomerase Activator. Statistically significant results were found in those taking TA-65 across several key conditions of aging:

    -- Improvement in immune system function

    -- Improvement in vision

    -- Enhancement of male sexual function

    -- Improvement in the condition of the skin

    -- Increased level of energy and sense of overall well being

The Pivotal 2005 Anti-Aging Trial was a double blind, placebo-controlled, 24 week study conducted in the USA involving 36 male subjects aged 60-85.

The most compelling result of the Trial was the profound and positive impact of TA-65 on the immune system, which normally declines with age, leading to many negative conditions commonly associated with aging.

Noel Thomas Patton, Founder and Chairman of TA Sciences said: "Taken together, the results of the Pivotal 2005 Anti-Aging Trial of TA-65 provide the first proof ever recorded of the vast, powerful, and tangible benefits of a Telomerase Activator in human aging. This trial has been invaluable to our establishment of the "PATTON PROTOCOL."

                        Find Out More on July 7, 2007


    On Saturday, July 7, 2007 at 6PM EST speakers include:


    -- Bill Andrews, Ph.D. Vice-President of research at Sierra Sciences Lab

       who, while Director of Molecular Biology at Geron Corporation was one

       of the principal discoverers of the telomerase genes.

    -- Jochen Kumm, Ph.D. Bio- Mathematics Director for the Stanford Genome

       Project.

    -- Physioage Medical Group Co-Founder Joseph Raffaele, M.D.

    -- TA Sciences founder Noel Patton.

The group will be disc ussing the details of the findings about TA-65 and answering caller questions. You can participate in this phone call at no cost, just by calling 1-866-463-5401 and entering a special code you can obtain by pre-registering at http://www.TASciences.com.

About TA Sciences:

The TA Sciences Center is located at 24 E. 64th Street in New York. The company offers its telomerase-activating molecule, TA-65, as part of the exclusive 12 month "PATTON PROTOCOL." TA-65 is sold under exclusive license from the Geron Corporation, the recognized worldwide leader in Telomere Biology.

CONTACT: TA Sciences, +1-212-588-8805

Web site: http://www.tasciences.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
2. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
3. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
4. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
5. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
6. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
9. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
10. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
11. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2017)... and INDIANAPOLIS , June 9, ... living with diabetes. In a further effort to help ... affected by this condition, the International Diabetes Federation (IDF) ... ) have come together for the second phase of ... Systems programme (BRIDGES 2), reaffirming their commitment to helping ...
(Date:6/8/2017)... MCKINNEY, Texas , June 8, 2017 ... Company"), a leading developer and manufacturer of ... industry, announced today that Cressey & Company ... investment firm, has completed a growth-focused investment ... acquired a majority ownership position from selling ...
(Date:6/7/2017)... URBANDALE, Iowa , June 6, 2017  Diplomat Specialty Infusion ... a sterile compounding environment to its Iowa ... Urbandale now features an ISO 7 cleanroom—the ... a controlled environment with a low level of pollutants. ... serve more IV nutrition consumers and better serve our ...
Breaking Medicine Technology:
(Date:6/24/2017)... ... June 24, 2017 , ... Genes Advice, a new ... select Florida and Texas doctors' offices and clinics. This breakthrough testing is part ... testing recognizes the role genes play in determining an individual's tolerance of and ...
(Date:6/24/2017)... ... June 24, 2017 , ... ... Located at 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and ... so that visits to the dentist fit into their patients’ busy lifestyles. Dental365 ...
(Date:6/24/2017)... ... June 24, 2017 , ... Doorknobs are for convenience, ... such as getting a guard dog or having an alarm system installed. But unless ... against forced entry. Yair Frenkel, owner of TX Premier Locksmith in Killeen, TX says: ...
(Date:6/23/2017)... ... June 23, 2017 , ... "The Better Care Reconciliation Act ... harm to people with all chronic conditions, including mental illnesses, while increasing the ... the Affordable Care Act (ACA) requirement that insurers cover pre-existing conditions, it does ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... Reconciliation Act (BCRA), their proposed healthcare bill to repeal and replace the Affordable ... the Senate bill would make significant cuts to Medicaid, a public health insurance ...
Breaking Medicine News(10 mins):